HC Wainwright Has Positive Outlook of ETON FY2024 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.15) for the year, up from their prior estimate of ($0.17). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.02) EPS and FY2025 earnings at $0.44 EPS.

Separately, Craig Hallum upped their price objective on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ ETON opened at $10.50 on Monday. The firm’s 50 day moving average price is $7.62 and its 200-day moving average price is $5.09. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $11.11. The company has a market cap of $271.32 million, a PE ratio of -47.73 and a beta of 1.25.

Insider Buying and Selling

In related news, major shareholder Opaleye Management Inc. acquired 57,500 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were bought at an average price of $4.65 per share, for a total transaction of $267,375.00. Following the completion of the transaction, the insider now directly owns 2,660,000 shares in the company, valued at approximately $12,369,000. This trade represents a 2.21 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders acquired 85,600 shares of company stock worth $462,674. 14.89% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Thompson Siegel & Walmsley LLC purchased a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth $420,000. Aristides Capital LLC bought a new position in Eton Pharmaceuticals in the second quarter valued at about $658,000. Acadian Asset Management LLC boosted its position in Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after purchasing an additional 18,898 shares during the last quarter. Renaissance Technologies LLC boosted its position in Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $3,095,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.